{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=53&state=Oregon",
    "query": {
      "state": "Oregon",
      "city": "Portland",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 9379,
    "total_pages": 938,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=54&state=Oregon&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=52&state=Oregon&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T23:40:24.377Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02983799",
      "title": "Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity"
      ],
      "interventions": [
        {
          "name": "OLAPARIB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 272,
      "start_date": "2016-12-22",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 35,
      "location_summary": "Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983799"
    },
    {
      "nct_id": "NCT04552899",
      "title": "A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "PRM-151 (Zinpentraxin Alfa)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 665,
      "start_date": "2021-03-19",
      "completion_date": "2023-02-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 64 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04552899"
    },
    {
      "nct_id": "NCT03942549",
      "title": "Changes in the Bladder Micro-environment Following Midurethral Sling Surgery for Stress Urinary Incontinence",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Stress Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Retropubic midurethral sling",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2019-05-03",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03942549"
    },
    {
      "nct_id": "NCT03940989",
      "title": "The Impact of Dosing Parameters on Motor Skill Acquisition and Retention in Bilateral Cerebral Palsy (BCP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cerebral Palsy"
      ],
      "interventions": [
        {
          "name": "HABIT-ILE",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Shriners Hospitals for Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2019-04-01",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-03-28",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 2,
      "location_summary": "New York, New York • Portland, Oregon",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03940989"
    },
    {
      "nct_id": "NCT01063855",
      "title": "Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Erectile Dysfunction",
        "Sexual Dysfunction"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapoxetine",
          "type": "DRUG"
        },
        {
          "name": "PDE5I (phosphodiesterase-5 inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 495,
      "start_date": "2010-04",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 19,
      "location_summary": "Decatur, Alabama • Huntsville, Alabama • Englewood, Colorado + 16 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01063855"
    },
    {
      "nct_id": "NCT02470585",
      "title": "Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Neoplasm"
      ],
      "interventions": [
        {
          "name": "Veliparib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Veliparib",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1140,
      "start_date": "2015-07-14",
      "completion_date": "2023-10-05",
      "has_results": true,
      "last_update_posted_date": "2024-10-26",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 135,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02470585"
    },
    {
      "nct_id": "NCT03006068",
      "title": "A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis (UC)"
      ],
      "interventions": [
        {
          "name": "Upadacitinib (ABT-494)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 950,
      "start_date": "2017-01-31",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 147,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03006068"
    },
    {
      "nct_id": "NCT00785291",
      "title": "Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "HER2/Neu Positive",
        "Progesterone Receptor Negative",
        "Progesterone Receptor Positive",
        "Recurrent Breast Carcinoma",
        "Stage IIIC Breast Cancer AJCC v6",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ixabepilone",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 799,
      "start_date": "2008-10-13",
      "completion_date": "2017-06-15",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 703,
      "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 472 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00785291"
    },
    {
      "nct_id": "NCT03447990",
      "title": "v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction",
        "Dilated Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "MYK-491",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 52,
      "start_date": "2018-02-06",
      "completion_date": "2019-10-24",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 9,
      "location_summary": "Jacksonville, Florida • Saint Paul, Minnesota • St Louis, Missouri + 6 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03447990"
    },
    {
      "nct_id": "NCT00437060",
      "title": "Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Childhood B Acute Lymphoblastic Leukemia",
        "Childhood T Acute Lymphoblastic Leukemia",
        "Cognitive Side Effects of Cancer Therapy",
        "Long-Term Effects Secondary to Cancer Therapy in Children",
        "Neurotoxicity Syndrome",
        "Psychological Impact of Cancer",
        "Untreated Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cognitive Assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "Diffusion Tensor Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Psychosocial Assessment and Care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 233,
      "start_date": "2007-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-11-18T23:40:24.377Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Downey, California • Long Beach, California + 83 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437060"
    }
  ]
}